The Anavex record; and future.
I just checked my records, to see when I bought my first Anavex Life Science Corp shares; May 2016. In the following years I’ve continued to buy more, when I have some discretionary budget dollars.
Now, for over six years, I’ve closely followed and scrutinized the particular (even peculiar) science of the Anavex molecules, trying to determine if it’s legitimate. Can blarcamesine (Anavex 2-72) really provide the multitude of therapeutic benefits imputed to it? Safely, without side effects?
All of that depends on just how the molecule works in cells. Until the last two years or so, how (or if) blarcamesine can work to resolve any of the central nervous system (CNS) diseases Anavex is targeting was legitimately questioned. The molecule’s “MOA,” mechanism of action, was both unknown and questioned. The early preclinical therapeutic results, in both murines (lab rodents) and humans were simply too good to be true. Too many things got fixed (or prevented), without any expected side effects. Virtually all drugs acting powerfully in the CNS have untoward side effects. None of those with blarcamesine.
Again, too good to be true.
But in the last two years or so the various mechanisms of action of blarcamesine in cells, in neurons in particular, have been discovered and elucidated. A number of detailed, definitive papers have been (independently) published, showing how this single small molecule is able to modulate, promote, and restore a diversity of cell processes, bringing functional health to the neurons and the tissues and organs they control.
Here’s the important fact, being evermore substantiated in both murine and human trials, in vitro (in isolated cells in glassware) and in vivo (in living organisms, murines and humans). So far, it has been discovered that blarcamesine, when attached as a ligand to the sigma-1 receptor protein in neurons, causes, facilitates a wide diversity of “downstream” processes in the cell; many of which are “cell-keeping” (homeostatic) processes. With restored or modulated homeostasis, cells, especially neurons, can function normally. Diseases and conditions are obviated. Health is restored or promoted.
But this is the even greater fact. Simply, just how many diseases and conditions can be either fixed or prevented by blarcamesine’s activation of the sigma-1 receptor protein is not yet known. It is becoming ever more clear that propitious activation of the sigma-1 receptor is not a fix for just three CNS diseases. It favorably modulates just a host of downstream chemical reaction cascades and processes that provide health to both cells and organs.
The prediction is this. Sigma-1 receptor activation biology will continue to be investigated and elucidated. Sigma-1 receptor activation biology is a new Big Thing; previously unrecognized.
Some have castigated Anavex’s long list of “pipeline” diseases blarcamesine might treat (or prevent). Too good to be true. No small molecule (molecular weight 281) can possibly have so many modulating or controlling effects within a cell.
Let’s watch. Continued investigations of the molecule almost surely will discover even more things it controls or modulates. Blarcamesine (and its analogues Anavex owns) is destined to be a major, even revolutionizing therapeutic in coming years. First with Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s. But after that, a widening diversity of human (and veterinary) diseases and conditions. By the end of the 2020s, medicine will not be the same. Nor will human health.
For the consideration by all, we welcome contrary posts, telling specifically why little or none of what I’ve conjectured can or will occur. Let’s see the contrary Anavex science. Lay it out for us, please.
